Literature DB >> 17471488

Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.

M Laé1, E H Ahn, G E Mercado, S Chuai, M Edgar, B R Pawel, A Olshen, F G Barr, M Ladanyi.   

Abstract

Paediatric rhabdomyosarcomas (RMS) are classified into two major subtypes based on histological appearance, embryonal (ERMS) and alveolar (ARMS), but this clinically critical distinction is often difficult on morphological grounds alone. ARMS, the more aggressive subtype, is associated in most cases with unique recurrent translocations fusing the PAX3 or PAX7 transcription factor genes to FKHR. In contrast, ERMS lacks unique genetic alterations. To identify novel diagnostic markers and potential therapeutic targets, we analysed the global gene expression profiles of these two RMS subtypes in 23 ARMS (16 PAX3-FKHR, 7 PAX7-FKHR) and 15 ERMS (all PAX-FKHR-negative) using Affymetrix HG-U133A oligonucleotide arrays. A statistically stringent supervised comparison of the ARMS and ERMS expression profiles revealed 121 genes that were significantly differentially expressed, of which 112 were higher in ARMS, including genes of interest as potential diagnostic markers or therapeutic targets, such as CNR1, PIPOX (sarcosine oxidase), and TFAPbeta. Interestingly, many known or putative downstream targets of PAX3-FKHR were highly overexpressed in ARMS relative to ERMS, including CNR1, DCX, ABAT, ASS, JAKMIP2, DKFZp762M127, and NRCAM. We validated the highly differential expression of five genes, including CNR1, DKFZp762M127, DCX, PIPOX, and FOXF1 in ARMS relative to ERMS by quantitative RT-PCR on an independent set of samples. Finally, we developed a ten-gene microarray-based predictor that distinguished ARMS from ERMS with approximately 95% accuracy both in our data by cross-validation and in an independent validation using a published dataset of 26 samples. The gene expression signature of ARMS provides a source of potential diagnostic markers, therapeutic targets, and PAX-FKHR downstream genes, and can be used to reliably distinguish these sarcomas from ERMS. Copyright 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17471488     DOI: 10.1002/path.2170

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  46 in total

1.  Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.

Authors:  Min-Hyung Lee; Mathivanan Jothi; Andrei V Gudkov; Asoke K Mal
Journal:  Cancer Res       Date:  2011-04-14       Impact factor: 12.701

Review 2.  Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.

Authors:  Roberta Ciarapica; Lucio Miele; Antonio Giordano; Franco Locatelli; Rossella Rota
Journal:  BMC Med       Date:  2011-05-25       Impact factor: 8.775

3.  Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.

Authors:  Erik Hedrick; Kumaravel Mohankumar; Alexandra Lacey; Stephen Safe
Journal:  Mol Cancer Res       Date:  2019-08-28       Impact factor: 5.852

4.  Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Authors:  Erin R Rudzinski; James R Anderson; Elizabeth R Lyden; Julia A Bridge; Frederic G Barr; Julie M Gastier-Foster; Karen Bachmeyer; Stephen X Skapek; Douglas S Hawkins; Lisa A Teot; David M Parham
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

Review 5.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

6.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Authors:  Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

7.  Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.

Authors:  Francesca Bersani; Marcello Francesco Lingua; Deborah Morena; Valentina Foglizzo; Silvia Miretti; Letizia Lanzetti; Giovanna Carrà; Alessandro Morotti; Ugo Ala; Paolo Provero; Roberto Chiarle; Samuel Singer; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto; Riccardo Taulli
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 12.701

8.  PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Authors:  Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

9.  Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype.

Authors:  S Ognjanovic; S E Carozza; E J Chow; E E Fox; S Horel; C C McLaughlin; B A Mueller; S Puumala; P Reynolds; J Von Behren; L Spector
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

10.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Authors:  Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.